Statistics from Altmetric.com
Randomised controlled non-inferiority trial.
Eight weeks (treatment period only).
66 centres, USA; enrolment June 2001 to September 2002.
673 adults (aged 18–65 years) with DSM-IV schizophrenia. Inclusion criteria: Positive and Negative Syndrome Scale (PANSS) total score ⩾60; score ⩾4 on delusions, conceptual disorganisation, hallucinations, suspiciousness, or persecution PANSS items; Clinical Global Impression Scale Severity of Illness score ⩾4; and evidence of deterioration in the 3 weeks prior to randomisation. Exclusions: other DSM-IV axis I disorder; intolerance or previous non-response to study drugs; use of clozapine in last month; psychotic …
For correspondence: D E Sweitzer, AstraZeneca Pharmaceuticals LP, 1800 Concord Pike, Wilmington, DE 19850, USA;
Source of funding: AstraZeneca.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.